A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

NCT07208149 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer (TNBC)

Interventions

DRUG: MR001 Bispecific Antibody for Injection

Sponsor

Shenzhen Majory Biotechnology Co., Ltd.